Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Asan Medical Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented pancreatic adenocarcinoma
Clinical T3 or T4 tumor according to AJCC staging system
Tumors considered as borderline resectable or unresectable disease assessed by multidisciplinary team including pancreatic surgeon, gastroenterologist specializing in pancreas, medical oncologist, and radiation oncologist
Age 18 years or older
ECOG performance status 2 or less
Adequate organ function
* Adequate bone marrow function (WBCs\> 3,500/µL, absolute neutrophil count \[ANC\]\> 1,500/µL, hemoglobin \> 9.0 g/dL, and platelets \> 100,000/µL)
* Adequate kidney function (creatinine \< 1.5 mg/dL)
* Adequate liver function (bilirubin \< 1.5 mg/dL \[\<2.5 mg/dL for patients with obstructive jaundice due to pancreatic cancer with adequate decompression\], transaminases levels \< 3 times the upper normal limit)
Patients must not have psychological, familial, sociological or geographical conditions which do not permit medical follow-up and compliance with this study
Women of childbearing potential must have a negative pregnancy test on admission. Post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Men and women of reproductive potential must have agreed to use an effective method of contraception while on treatment and for 6 months after study treatment
The patient must be able to understand the study and has given written informed consent to participate in the study
You may not be if
Other tumor type than adenocarcinoma
Evidence of gastrointestinal bleeding or obstruction
Presence of the clinically relevant ascites or distant metastases
Past or concurrent history of malignant neoplasm, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri
Pregnant or lactating women, women of childbearing potential not employing adequate contraception
Hypersensitivity to any of the study drugs or ingredients
Other serious illness or medical conditions
* Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
* History of significant neurologic or psychiatric disorders including dementia or seizures
* Active uncontrolled infection
* Pre-existing clinically significant diarrhea
* Active peptic ulcer
* Severe hypercalcemia of 12 mg/dL uncontrolled with bisphosphonates
* Active disseminated intravascular coagulation
* Other serious underlying medical conditions which could impair the ability of the patient to participate in the study
Concomitant or administration of any other experimental drug under investigation within 3 weeks before the study
Concomitant chemotherapy, hormonal therapy, or immunotherapy
Clareo Health | Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer
